Tuesday, October 16, 2018

MannKind, United Therapeutics Close Licensing Deal

Westlake Village-based MannKind, which is developing inhaled threapeutics products for treating such diseases as diabetes and pumnoary arterial hypertension, and partner United Therapeutics Corporation, said this morning that the two have closed on a license and collaboration agreement they had originally announced in September. The two had announced the deal--worth up to $95M--in September, where the would collaborate over development and commercialization of a dry powder formatuion of treprostinil which is being developed for the treatment of pulmonary arterial hypertension. That deal includes $45M upfront, plus up to $50M in potential milestone payments. The two said the deal closed after the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.